Archive for October, 2015

« Previous Entries

FDA approves new inhaled spray for COPD

Monday, October 19th, 2015

The US Food and Drug Administration (FDA) has approved olodaterol (brand name Striverdi Respimat) for treating chronic obstructive pulmonary disease (COPD). Striverdi Respimat is an inhaled spray and comes under the class of drugs known as long-acting beta-adrenergic agonists (LABAs). According to the FDA, the medicine works by keeping the airway muscles relaxed. It is […]

Chronic heartburn drugs linked to higher kidney disease

Sunday, October 18th, 2015

According to two new studies, proton pump inhibitors (PPIs) may be linked to a greater risk of chronic kidney disease. PPIs are commonly indicated for heartburn. PPIs include the drugs Prilosec, Nexium and Prevacid. Although the current studies did find a correlation between the drugs and chronic kidney disease, there was no causal relationship established. […]

FDA approves MorphaBond with abuse-deterrent properties

Thursday, October 15th, 2015

The US Food and Drug Administration (FDA) has approved Inspirion Delivery Technologies’ MorphaBond (morphine sulfate) extended-release oral tablets featuring abuse-deterrent properties. MorphaBond is an abuse-deterrent ER-morphine that uses chemical and physical barriers without opioid antagonists or aversive agents. It features inactive ingredients that make the drug more difficult to adulterate for abuse or misuse, all […]

FDA approves aripiprazole lauroxil for schizophrenia

Wednesday, October 14th, 2015

The US Food and Drug Administration (FDA) has approved a new drug called aripiprazole lauroxil (brand name Aristada) for the treatment of adults with schizophrenia. The drug is an extended-release injection recommended to be administered every four-six weeks. Mitchell Mathis, director of the Division of Psychiatry Products in the Center for Drug Evaluation and Research, […]

FDA approves nivolumab for advanced lung cancer

Tuesday, October 13th, 2015

The US Food and Drug Administration (FDA) has extended the approved use of nivolumab (brand name Opdivo) for the treatment of advanced metastatic non-small cell lung cancer (NSCLC) in patients whose disease progressed after or during platinum-based chemotherapy. Nivolumab works by targeting the PD-1/PD-L1 cellular pathway, helping the immune system fight the cancer cells. It […]

Younger women less likely to take post-heart attack meds

Monday, October 12th, 2015

According to new Canadian research, younger women are less likely than men to take the necessary heart medications a year after suffering from a heart attack. The study underscores previous data that indicate that fewer women take the drugs. The study was co-authored by Karin Humphries, an associate professor of cardiology at the University of […]

Prescription painkiller abuse declines in past decade

Sunday, October 11th, 2015

A new study by the US Substance Abuse and Mental Health Services Administration’s Center for Behavioral Health Statistics and Quality has found that prescription narcotic painkiller abuse rates have declined slightly in the last ten years. Despite the decline, the continuing abusers are using the drugs more frequently and are more likely to get addicted. […]

Chantix may help women faster than men

Saturday, October 10th, 2015

According to a study from the Yale School of Medicine, the smoking cessation medication varenicline (brand name Chantix) worked better for women than men in the first year of treatment. A year later, it worked equally well for both genders. The study was led by Sherry McKee, professor of psychiatry, who said, “Studies show that […]

Flu vaccine for 2015 predicted to be ‘good match’

Friday, October 9th, 2015

According to experts, including US Centers for Disease Control and Prevention (CDC) officials, the flu vaccine for 2015 may be particularly well-suited to fight the disease this season. Experts claimed that the 2015 vaccine is a ‘good match’ against major flu virus strains this season, and will be more successful in preventing the disease than […]

Clomiphene more effective than letrozole for unexplained infertility

Thursday, October 8th, 2015

According to a new study, the drug clomiphene may have greater effectiveness than letrozole for treating unexplained infertility. The study was led by Esther Eisenberg, of the National Institutes of Health (NIH), and it found that clomiphene, which is the standard treatment for unexplained infertility in women, may result in a larger number of live […]

« Previous Entries